Mineralys and the Second Renaissance of Hypertension Research By Mark TerryMay 5, 2023 Mineralys Therapeutics, headquartered in Radnor, Pa., dosed the first patient in its ADVANCE-HTN pivotal trial of lorundrostat [….]
Mineralys and the Second Renaissance of Hypertension Research By Mark TerryMay 5, 2023 Mineralys Therapeutics, headquartered in Radnor, Pa., dosed the first patient in its ADVANCE-HTN pivotal trial of lorundrostat [….]